LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.9745 USD -10.6%
Market Cap: 25.6m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LAVA Therapeutics NV
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Revenue
$6.8m
CAGR 3-Years
25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Revenue
$285.7m
CAGR 3-Years
-7%
CAGR 5-Years
12%
CAGR 10-Years
51%
ProQR Therapeutics NV
NASDAQ:PRQR
Revenue
€21.3m
CAGR 3-Years
113%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Revenue
$28.6m
CAGR 3-Years
-61%
CAGR 5-Years
36%
CAGR 10-Years
18%
argenx SE
XBRU:ARGX
Revenue
$1.9B
CAGR 3-Years
44%
CAGR 5-Years
87%
CAGR 10-Years
126%
Merus NV
NASDAQ:MRUS
Revenue
$35.9m
CAGR 3-Years
-6%
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
25.6m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.1828 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Revenue?
Revenue
6.8m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Revenue amounts to 6.8m USD.

What is LAVA Therapeutics NV's Revenue growth rate?
Revenue CAGR 3Y
25%

Over the last year, the Revenue growth was -65%. The average annual Revenue growth rates for LAVA Therapeutics NV have been 25% over the past three years .

Back to Top